stockrow
Monday 9 November 2026
Export CNTN’s income statement to Excel — free account
Canton Strategic Holdings, Inc.
CNTN- EPS
- +85.9%
- Free cash flow
- −600.4%
Quarter to June 2026, against a year earlier
2.06
0.13
+6.74%
Follow CNTN
Alert me
Canton Strategic Holdings, Inc. (CNTN) P/E ratio
Canton Strategic Holdings, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ANTX AN2 Therapeutics, Inc. compare | n/m |
| ALXO ALX Oncology Holdings Inc. compare | n/m |
| IPHA Innate Pharma S.A. Sponsored ADR compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| PEPG PepGen, Inc. compare | n/m |
| CNTN Canton Strategic Holdings, Inc. | n/m |
| STRO Sutro Biopharma, Inc. compare | n/m |
| INO Inovio Pharmaceuticals, Inc. compare | n/m |
| ORMP Oramed Pharmaceuticals Inc. compare | 0.9× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)